IgA Nephropathy (Berger’s Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3495
Buy Report View Sample

Published: August 29, 2023 Report Code: GDHC128CL-ST

Select Item

IgA Nephropathy Competitive Analysis Report Overview

IgA Nephropathy (Berger’s disease) is an autoimmune disease that occurs when clumps of antibodies are deposited in the kidneys, causing inflammation and kidney damage. Clumps of IgA and other antibodies damage the glomeruli, tiny blood vessels in the kidneys that filter blood, causing the kidneys to leak blood and protein into the urine. The damage may also lead to scarring of the nephrons, the filtering units where the glomeruli are located.

Key Mechanism of Action (Marketed) ·       Enzyme Inhibitor

·       Receptor Agonist

·       Receptor Antagonist
Key Routes of Administration (Marketed) ·       Oral

·       Injection

The IgA Nephropathy (Berger’s Disease) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase transition success rate (PTSR) and the likelihood of approval (LoA) for IgA Nephropathy (Berger’s Disease). The report also analyzes the clinical and commercial landscapes of Berger’s Disease, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Key Mechanisms of Action (Pipeline) ·       Enzyme Inhibitor

·       Cytotoxic to cell

·       Biological Factor Inhibitor

·       Receptor antagonist

·       Receptor Agonist
Key Routes of Administration (Pipeline) ·       Injection

·       Oral
Top Sponsors (Marketed and Pipeline Drugs) ·       Chinook Therapeutics

·       Travere Therapeutics

·       Alexion Pharmaceuticals

·       Novartis AG

·       Ruijin Hospital

·       Peking Union Medical College Hospital
Enquire & Decide Discover the perfect solution for your business needs.  Enquire now and let us help you make an informed decision before making a purchase.

Berger’s Disease Marketed Drugs Segmentation by Mechanisms of Action

Enzyme inhibitor, receptor agonist, and receptor antagonist are the key MoA in the Berger’s Disease marketed drugs market. Most marketed drugs for Berger’s Disease are enzyme inhibitor.

Berger’s Disease Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)

Berger’s Disease Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)

Buy Full Report to Know More about the MoA of Berger’s Disease Marketed Drugs

Download a Free Report Sample

Berger’s Disease Marketed Drugs Segmentation by Routes of Administration

The key routes of administration for Berger’s Disease marketed drugs are oral and injection. In 2023, most of the marketed drugs available for Berger’s Disease are given by oral RoA.

Berger’s Disease Marketed Drugs Analysis by Routes of Administration, 2023 (%)

Berger’s Disease Marketed Drugs Analysis by Routes of Administration, 2023 (%)

Buy Full Report to Know More about the RoA of Berger’s Disease Marketed Drugs

Download a Free Report Sample

Berger’s Disease Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action for Berger’s Disease pipeline drugs are enzyme inhibitor, cytotoxic to cell, biological factor inhibitor, receptor antagonist, and receptor agonist among others. In 2023, most of the drugs in the Berger’s Disease pipeline are enzyme inhibitor.

Berger’s Disease Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)

Berger’s Disease Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)

Buy Full Report to Know More about the MoA of Berger’s Disease Pipeline Drugs

Download a Free Report Sample

Berger’s Disease Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration for Berger’s Disease pipeline drugs are injection and oral. Most pipeline drugs for Berger’s Disease are injection therapies.

Berger’s Disease Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)

Berger’s Disease Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)

Buy Full Report to Know More about the RoA of Berger’s Disease Pipeline Drugs

Download a Free Report Sample

Berger’s Disease Marketed and Pipeline Drugs Market – Competitive Landscape

Some of the top sponsors in the Berger’s Disease marketed and pipeline drugs market are the Chinook Therapeutics, Travere Therapeutics, Alexion Pharmaceuticals, Novartis AG, Ruijin Hospital, and Peking Union Medical College Hospital, among others. In 2023, the Chinook Therapeutics leads among the trial sponsors after adding up all the trial phases.

Berger’s Disease Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)

Berger’s Disease Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)

Buy the Full Report for More Sponsor Insights into the Berger’s Disease Marketed and Pipeline Drugs Market

Download a Free Report Sample

Segments Covered in the Report

Berger’s Disease Marketed Drugs Mechanism of Action (Number of Drugs, 2023)

  • Enzyme Inhibitor
  • Receptor Agonist
  • Receptor Antagonist

Berger’s Disease Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)

  • Injection
  • Oral

Berger’s Disease Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)

  • Cytotoxic to cell
  • Biological Factor Inhibitor
  • Enzyme Inhibitor
  • Receptor antagonist
  • Receptor Agonist

Berger’s Disease Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)

  • Injection
  • Oral

Scope

Components of the report include –

  • Disease Landscape

  • Disease Overview

  • Epidemiology Overview

  • Treatment Overview

  • Marketed Products Assessment

  • Breakdown by Mechanism of Action, Route of Administration

  • Product Profiles with Sales Forecast

  • Pricing and Reimbursement Assessment

  • Annual Therapy Cost

  • Time to Pricing and Time to Reimbursement

  • Pipeline Assessment

  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

  • Product Profiles with Sales Forecast

  • Late-to-mid-stage Pipeline Drugs

  • Phase Transition Success Rate and Likelihood of Approval

  • Clinical Trials Assessment

  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

  • Enrolment Analytics, Site Analytics, Feasibility Analysis

  • Deals Landscape

  • Mergers, Acquisitions, and Strategic Alliances by Region

  • Overview of Recent Deals

  • Commercial Assessment

  • Key Market Players

  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the Berger’s Disease market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Berger’s Disease market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface_x000D_

1.1 Contents_x000D_

1.2 Report Scope_x000D_

1.3 List of Tables and Figures_x000D_

1.4 Abbreviations_x000D_

2 Key Findings_x000D_

3 Disease Landscape_x000D_

3.1 Disease Overview_x000D_

3.2 Epidemiology Overview_x000D_

3.3 Treatment Overview _x000D_

4 Marketed Drugs Assessment_x000D_

4.1 Leading Marketed Drugs_x000D_

4.2 Overview by Mechanism of Action_x000D_

4.3 Overview by Route of Administration_x000D_

4.4 Marketed Drugs Profiles and Sales Forecasts_x000D_

5 Pricing and Reimbursement Assessment_x000D_

5.1 Annual Therapy Cost_x000D_

5.2 Time to Pricing and Reimbursement_x000D_

6 Pipeline Drugs Assessment_x000D_

6.1 Phase III Pipeline Drugs_x000D_

6.2 Overview by Development Stage_x000D_

6.3 Overview by Molecule Type_x000D_

6.4 Overview by Mechanism of Action_x000D_

6.5 Overview by Route of Administration_x000D_

6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)_x000D_

6.7 Therapy Area and Indication-specific PTSR and LoA_x000D_

7 Clinical Trials Assessment_x000D_

7.1 Historical Overview_x000D_

7.2 Overview by Phase_x000D_

7.3 Overview by Status_x000D_

7.4 Overview by Phase for Ongoing and Planned Trials_x000D_

7.5 Trials with Virtual Components_x000D_

7.6 Geographic Overview_x000D_

7.7 Single-Country and Multinational Trials by Region_x000D_

7.8 Top 20 Sponsors with Breakdown by Phase_x000D_

7.9 Top 20 Sponsors with Breakdown by Status_x000D_

7.10 Overview by Endpoint Status_x000D_

7.11 Overview by Race and Ethnicity_x000D_

7.12 Enrollment Data_x000D_

7.13 Top 20 countries for Trial Sites_x000D_

7.14 Top 20 Sites Globally_x000D_

7.15 Feasibility Analysis – Geographic Overview_x000D_

7.16 Feasibility Analysis – Benchmark Models_x000D_

8 Deals Landscape_x000D_

8.1 Mergers, Acquisitions, and Strategic Alliances by Region_x000D_

8.2 Recent Mergers, Acquisitions, and Strategic Alliances_x000D_

9 Commercial Assessment_x000D_

9.1 Key Market Players_x000D_

10 Future Market Catalysts_x000D_

11 Appendix_x000D_

11.1 Methodology_x000D_

11.2 Methodology – Sales Forecast_x000D_

11.3 Methodology – Pricing and Reimbursement_x000D_

11.4 Methodology – PTSR and LoA Analysis_x000D_

11.5 About the Authors_x000D_

11.6 Contact Us_x000D_

11.7 Disclaimer

Frequently asked questions

IgA Nephropathy (Berger’s Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape thematic reports
Currency USD
$3,495

Can be used by individual purchaser only

Most Popular
$6,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

IgA Nephropathy (Berger’s Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more IgA Nephropathy (Berger's Disease) reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at IgA Nephropathy (Berger’s Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape in real time.

  • Access a live IgA Nephropathy (Berger’s Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more